# RELATIVITY-1093 (NCT06561386)

> A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

No report yet. It can be ordered.

- Drugs tested: nivolumab plus relatlimab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06561386
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-small Cell Lung Cancer
- Interventions: Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin
- Enrollment: 1000
- Primary outcome: Overall survival (OS) in randomized participants with PD-L1 1% to 49%

## Indexed commentary on RELATIVITY-1093 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 3
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=relativity-1093-nct06561386